Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dizziness, Gluten sensitivity, Headache, Inflammatory marker test
Clinical narrative: Gluten intolerance; Diarrhea; headache/ headaches; Dizziness; This spontaneous case was reported by a consumer and describes the occurrence of GLUTEN SENSITIVITY (Gluten intolerance), DIARRHOEA (Diarrhea), DIZZINESS (Dizziness) and HEADACHE (headache/ headaches) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003A21A and 011M20A) for COVID-19 vaccination.     The patient's past medical history included Gluten free diet (With which diarrhea stopped.) since 15-Apr-2021. Concomitant products included PLANTAGO OVATA (METAMUCIL CITRON) for PRODUCT USED FOR UNKNOWN INDICATION, BIFIDOBACTERIUM INFANTIS (ALIGN) for Probiotic therapy, VALSARTAN (DIOVAN), CLONIDINE, CYCLOBENZAPRINE, TRAMADOL, TEMAZEPAM, PARACETAMOL (TYLENOL), BIOTIN, ASCORBIC ACID, CALCIUM, MINERALS NOS, RETINOL, TOCOPHERYL ACETATE, VITAMIN B NOS, VITAMINS NOS, ZINC (CENTRUM SILVER [ASCORBIC ACID;CALCIUM;MINERALS NOS;RETINOL;TOCOPHERYL ACETATE;VITAMIN B NOS;VITAMINS NOS;ZINC]), OSTEO BI-FLEX [ASCORBIC ACID;BOSWELLIA SERRATA RESIN;CHONDROITIN SULFATE;COLLAGEN;GLUCOSAMINE HYDROCHLORIDE;HYALURONIC ACID;MANGANESE SULFATE;METHYLSULFONYLMETHANE;SODIUM;SODIUM BORATE], KRILL OIL (MEGARED OMEGA 3 KRILL OIL), MAGNESIUM CARBONATE (MAGENSIUM VITAFIT), CALCIUM CARBONATE (OSCAL [CALCIUM CARBONATE]) and MELATONIN for an unknown indication.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced DIZZINESS (Dizziness). On 18-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HEADACHE (headache/ headaches). On 19-Mar-2021, the patient experienced DIARRHOEA (Diarrhea). On an unknown date, the patient experienced GLUTEN SENSITIVITY (Gluten intolerance). The patient was treated with LOPERAMIDE HYDROCHLORIDE (LOMOTIL [LOPERAMIDE HYDROCHLORIDE]) for Diarrhea, at an unspecified dose and frequency; LOPERAMIDE HYDROCHLORIDE (IMODIUM) for Diarrhea, at an unspecified dose and frequency; METRONIDAZOLE (FLAGYL [METRONIDAZOLE]) at a dose of 4 doses; SULFAMETHOXAZOLE at an unspecified dose and frequency and MECLOZINE HYDROCHLORIDE (MECLIZINE [MECLOZINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, GLUTEN SENSITIVITY (Gluten intolerance), DIARRHOEA (Diarrhea), DIZZINESS (Dizziness) and HEADACHE (headache/ headaches) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Apr-2021, Inflammatory marker test: high (High) 9x the normal level.         On 19-Apr-2021 patient had test for celiac disease- result is negative On an unknown date, blood test performed to measure inflammation, results are unknown.   Most recent FOLLOW-UP information incorporated above includes: On 07-Aug-2021: Follow-up received on 7-AUG-2021. Contains, Laboratory details added, intensity and outcome of the events headaches and dizziness was updated, medical history and concomitant medication details.